US FDA seeks to accelerate clinical trials of new medicines by using AI to streamline the laborious process of collecting and submitting study data
Context
The FDA's move to use AI in streamlining clinical trials indicates a potential shift in how quickly new medicines can reach the market. This could enhance the innovation landscape and improve investor sentiment towards biotech and healthcare sectors. Overall, it positions the U.S. as a leader in integrating technology into healthcare, which may have broader implications for the equities market.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#FDA#EU SESSION#US SESSION#US EQUITIES#AI